Potential of Blood-based Biomarker Approaches in Endometrium and Breast Cancer: a Case-control Comparison Study

Overview

Journal Arch Gynecol Obstet

Specialty Gynecology & Obstetrics

Date 2022 Mar 14

PMID 35284957

Authors

Anne Schuhn

Tania Witte Tobar

Aoife Ward Gahlawat

Jana Hauke

Lukas Baumann

Jurgen G Okun

Juliane Nees

Affiliations

Soon will be listed here.

Abstract

Purpose: Endometrial carcinoma is the second most common gynecological malignancy. Until today lacking a screening tool. A blood-based biomarker could help address this need.

Methods: The expression levels of 30 acylcarnitines, 18 amino acids, 6 miRNAs, and 7 DNA methylation sites were measured in blood samples from 331 women (20 EC, 14 benign uterine lesions (benign), 140 breast cancers (BC), 157 controls). Areas under the ROC curves (AUC), sensitivity (sens.) and specificity (spec.) were computed to identify the variables best distinguishing.

Results: The best top ten markers for the four comparisons (cancer vs. cancer-free; EC vs. BC, EC vs. controls; EC vs. benign), were identified via AUC. Malonylcarnitine distinguished best patients with EC from controls (AUC: 0.827, sens. 80%, spec. 73.1%) or BC (AUC: 0.819, sens. 84.3%, spec. 80%) being most notable. Tryptophan best differentiated benign from EC (AUC: 0.846, sens. 70%, spec. 92.9%).

Conclusions: The levels of the analyzed blood markers yielded promising results in the detection of EC and warrant further evaluation.

Citing Articles

Unveiling DNA methylation: early diagnosis, risk assessment, and therapy for endometrial cancer.

Li M, Xia Z, Wang R, Xi M, Hou M Front Oncol. 2025; 14:1455255.

PMID: 39902129 PMC: 11788147. DOI: 10.3389/fonc.2024.1455255.

Research Progress of DNA Methylation Markers for Endometrial Carcinoma Diagnosis.

Zheng H, Yu C, Yang L, Zhou F, Liu A J Cancer. 2025; 16(3):812-820.

PMID: 39781343 PMC: 11705058. DOI: 10.7150/jca.104214.

Endometrial cancer diagnostic and prognostic algorithms based on proteomics, metabolomics, and clinical data: a systematic review.

Romano A, Rizner T, Werner H, Semczuk A, Lowy C, Schroder C Front Oncol. 2023; 13:1120178.

PMID: 37091170 PMC: 10118013. DOI: 10.3389/fonc.2023.1120178.

Diagnostic Accuracy of Liquid Biomarkers for the Non-Invasive Diagnosis of Endometrial Cancer: A Systematic Review and Meta-Analysis.

Karkia R, Wali S, Payne A, Karteris E, Chatterjee J Cancers (Basel). 2022; 14(19).

PMID: 36230588 PMC: 9563808. DOI: 10.3390/cancers14194666.

References

Miyagi Y, Higashiyama M, Gochi A, Akaike M, Ishikawa T, Miura T . Plasma free amino acid profiling of five types of cancer patients and its application for early detection. PLoS One. 2011; 6(9):e24143. PMC: 3168486. DOI: 10.1371/journal.pone.0024143. View

Hatse S, Brouwers B, Dalmasso B, Laenen A, Kenis C, Schoffski P . Circulating MicroRNAs as easy-to-measure aging biomarkers in older breast cancer patients: correlation with chronological age but not with fitness/frailty status. PLoS One. 2014; 9(10):e110644. PMC: 4204997. DOI: 10.1371/journal.pone.0110644. View

Park J, Shin Y, Kim T, Kim D, Lee A . Plasma metabolites as possible biomarkers for diagnosis of breast cancer. PLoS One. 2019; 14(12):e0225129. PMC: 6890236. DOI: 10.1371/journal.pone.0225129. View

Zhang C, Wang B, Wu L . MicroRNA‑409 may function as a tumor suppressor in endometrial carcinoma cells by targeting Smad2. Mol Med Rep. 2018; 19(1):622-628. DOI: 10.3892/mmr.2018.9642. View

Steiber A, Kerner J, Hoppel C . Carnitine: a nutritional, biosynthetic, and functional perspective. Mol Aspects Med. 2004; 25(5-6):455-73. DOI: 10.1016/j.mam.2004.06.006. View

Liu W, Liu Y, Yang Y, Ou W, Chen X, Huang B . Metabolic Biomarkers of Aging and Aging-related Diseases in Chinese Middle-Aged and Elderly Men. J Nutr Health Aging. 2018; 22(10):1189-1197. DOI: 10.1007/s12603-018-1062-0. View

Wilhelm T, Lipka D, Witte T, Wierzbinska J, Fluhr S, Helf M . Epigenetic silencing of AKAP12 in juvenile myelomonocytic leukemia. Epigenetics. 2016; 11(2):110-9. PMC: 4846096. DOI: 10.1080/15592294.2016.1145327. View

Baroukh N, Van Obberghen E . Function of microRNA-375 and microRNA-124a in pancreas and brain. FEBS J. 2010; 276(22):6509-21. DOI: 10.1111/j.1742-4658.2009.07353.x. View

Mai M, Tonjes A, Kovacs P, Stumvoll M, Fiedler G, Leichtle A . Serum levels of acylcarnitines are altered in prediabetic conditions. PLoS One. 2013; 8(12):e82459. PMC: 3865089. DOI: 10.1371/journal.pone.0082459. View

10.

Li D, Sun H, Bai G, Wang W, Liu M, Bao Z . α-1,3-Fucosyltransferase-VII siRNA inhibits the expression of SLex and hepatocarcinoma cell proliferation. Int J Mol Med. 2018; 42(5):2700-2708. PMC: 6192724. DOI: 10.3892/ijmm.2018.3850. View

11.

Ali O, Shabayek M, Seleem M, Abdelaziz H, Makhlouf D . MicroRNAs 182 and 375 Sera Expression as Prognostic Biochemical Markers in Breast Cancer. Clin Breast Cancer. 2018; 18(6):e1373-e1379. DOI: 10.1016/j.clbc.2018.07.020. View

12.

Mihalik S, Goodpaster B, Kelley D, Chace D, Vockley J, Toledo F . Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. Obesity (Silver Spring). 2010; 18(9):1695-700. PMC: 3984458. DOI: 10.1038/oby.2009.510. View

13.

Cheng Y, Ban R, Liu W, Wang H, Li S, Yue Z . MiRNA-409-3p enhances cisplatin-sensitivity of ovarian cancer cells by blocking the autophagy mediated by Fip200. Oncol Res. 2018; . DOI: 10.3727/096504017X15138991620238. View

14.

Canlorbe G, Wang Z, Laas E, Bendifallah S, Castela M, Lefevre M . Identification of microRNA expression profile related to lymph node status in women with early-stage grade 1-2 endometrial cancer. Mod Pathol. 2016; 29(4):391-401. DOI: 10.1038/modpathol.2016.30. View

15.

Hein A, Schneider M, Renner S, Fasching P, Fiessler C, Titz S . Risk of postmenopausal hormone therapy and patient history factors for the survival rate in women with endometrial carcinoma. Arch Gynecol Obstet. 2019; 301(1):289-294. DOI: 10.1007/s00404-019-05414-3. View

16.

Arioz D, Kanat-Pektas M, Tuncer N, Koken T, Unlu B, Koken G . L-Carnitine: a new insight into the pathogenesis of endometrial cancer. Arch Gynecol Obstet. 2014; 291(5):1147-52. DOI: 10.1007/s00404-014-3507-y. View

17.

Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S . The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Curr Protoc Bioinformatics. 2016; 54:1.30.1-1.30.33. DOI: 10.1002/cpbi.5. View

18.

Nees L, Heublein S, Steinmacher S, Juhasz-Boss I, Brucker S, Tempfer C . Endometrial hyperplasia as a risk factor of endometrial cancer. Arch Gynecol Obstet. 2022; 306(2):407-421. PMC: 9349105. DOI: 10.1007/s00404-021-06380-5. View

19.

He Z, Xu H, Meng Y, Kuang Y . miR-944 acts as a prognostic marker and promotes the tumor progression in endometrial cancer. Biomed Pharmacother. 2017; 88:902-910. DOI: 10.1016/j.biopha.2017.01.117. View

20.

Qiao R, Di F, Wang J, Wei Y, Zhang Y, Xu T . The Association Between RAPSN Methylation in Peripheral Blood and Early Stage Lung Cancer Detected in Case-Control Cohort. Cancer Manag Res. 2020; 12:11063-11075. PMC: 7646459. DOI: 10.2147/CMAR.S275321. View